Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer

Abstract

High Ki-67 immunohistochemical expression levels in distant metastatic lesions were independently associated with poorer overall survival outcomes after biopsy of recurrence lesion in breast cancer patients.

Effect of KI-67 positive cellular index on prognosis after hepatectomy in Barcelona Clinic Liver Cancer stage A and B hepatocellular carcinoma with microvascular invasion

“… 21 Studies have confirmed that KI-67 expression could be regarded as a poor prognosis predictor in several types of cancers. For instance, high levels of KI-67 expression in distant metastatic lesions have been shown to predict a poor overall survival outcome in breast cancer; 23 elevated expression of KI-67 was associated with tumor metastasis and could be employed as a prognostic factor in gastroenteropancreatic neuroendocrine tumors; 35 KI-67 expression may play a critical role in predicting prognosis of astrocytomas and should be routinely examined in patients with astrocytomas. 36 In our study, we found that the median RFS in patients with high KI-67 positive cellular index was only 7 months, while RFS reached 31 months in patients with low positive cellular index ( P <0.001).…”

“… 20 , 21 KI-67 has a close relationship with breast cancer, but has also been examined as a predictor of postoperative recurrence for several types of tumors, including HCC. 22 , 23 Several reports have indicated that the increase in growth fraction of hepatocytes could exert a considerable influence on hepatocarcinoma and KI-67 positive cellular index is the highest in HCC but lowest in normal liver tissue. 24 , 25 The influence of KI-67 on HCC prognosis has been debated, but several investigations suggest KI-67 is not a poor prognostic factor.…”

Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients

“…Ki-67/MKI67 exists in G1, S, G2 and mitosis phases of cell cycle 7 and can be put into clinical practice by acting as an index to evaluate cell proliferation by immunohistochemical staining 8. A large number of studies have reported the clinical and prognostic value of Ki-67/MKI67 in various malignancies, such as breast cancer 9, cervical cancer 10, glioma 11, colorectal cancer 12 and hepatocellular carcinoma 13. Our research group previously conducted systematic meta-analyses to explore the prognostic role of Ki-67/MKI67 in lung cancer 14, hepatocellular carcinoma 13, cervical cancer 15, glioma 16 and colorectal cancer 17 and found that Ki-67/MIB-1 could be an independent prognostic biomarker in these types of carcinoma.…”

A Necessidade Do Diagnóstico Para Definição Terapêutica Da Aman, Variante Da Síndrome De Guillain Barré

“…O ki67 é um marcador imuno-histoquímico que está presente nas células em proliferação e é utilizado como fator de risco na determinação da estratégia terapêutica a ser utilizada no tratamento do carcinoma da mama. Alguns estudos demonstraram que os níveis altos de expressão imuno-histoquímica do Ki-67 em lesões metastáticas distantes foram independentemente associados a piores prognósticos (POLLEY et al, 2015;DOWSETT et al, 2011;INCA, 2017;INARI et al, 2017) e, quanto maior o seu índice, maior a proliferação celular, sendo um dos mais importantes marcadores imuno-histoquímicos no diagnóstico dos cânceres em geral. Sua medição é realizada a partir da porcentagem de células coradas com um reagente específico, e cortes diferentes variam para cada tipo de câncer (INCA, 2017;CSERNI, 2014).…”